Ferring International Center SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.
This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.
This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.
Scope
- Business description - A detailed description of the company’s operations and business divisions.
- Corporate strategy - The analyst’s summarization of the company’s business strategy.
- SWOT analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives’ employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list of key locations and subsidiaries of the company, including contact details.
Highlights
Ferring International Center SA (Ferring), a subsidiary of Ferring Holding SA, is a research-driven, specialty biopharmaceutical company. Its primary activities include research and development in reproductive medicine, women's health, gastroenterology and urology. Ferring's product portfolio includes treatments for reproductive medicine and maternal health, gastroenterology and microbiome, urology and uro-oncology, endocrinology and orthopedics. Ferring's products are used by patients seeking treatments in the areas of reproductive health, gastroenterology, and urology, among others. The company has a global presence with manufacturing sites and R&D centers in countries such as China, Denmark, Brazil, Israel, Japan, India, the UK, and the US. Ferring Pharmaceuticals is headquartered in Saint-Prex, Switzerland.Ferring International Center SA Key Recent Developments
- Jul 23, 2024: Ferring Pharmaceuticals Appoints Michael Rosenblatt to Board of Directors
- Jul 23, 2024: Dr. Michael Rosenblatt joins Ferring Pharmaceuticals’ Board of Directors
- Apr 09, 2024: Launch of Two First-In-Class Medicines in 2023 Marks Start of Exciting Phase of Growth for Ferring
- Sep 06, 2023: BII and Ferring jointly support FimmCyte through the Venture House program
Reasons to Buy
- Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
- Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
- Understand and respond to your competitors’ business structure and strategies with the analyst’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
- Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
Table of Contents
Section 1 - About the Company
Section 2 - Company Analysis
Section 3 - Company’s Lifesciences Financial Deals and Alliances
Section 4 - Company’s Recent Developments
Section 5 - Appendix
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Max Zeller Soehne AG
- Release Therapeutics
- SLA Pharma AG
- Mepha Pharma AG
- Med Discovery SA